All In Biotech

Drug Trial Radar · NCT05958875

The Effect of a Six Week Intensified Pharmacological Treatment for Schizophrenia Compared to Treatment as Usual in Subjects Who Had a First-time Treatment Failure on Their First-line Treatment.

A Randomised, Controlled Trial to Investigate the Effect of a Six Week Intensified Pharmacological Treatment for Schizophrenia Compared to Treatment as Usual in Subjects Who Had a First-time Treatment Failure on Their First-line Treatment.

Last checked: Nov 19, 2026Latest source record: Sep 26, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 418 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

418

Planned (sponsor's estimate)

Start

Aug 1, 2024

Primary completion

Jun 30, 2028

Study completion Jun 30, 2028

Sponsor

Lead sponsor
Dr. Inge WinterAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Universität Münster
First posted
Jul 25, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Single (outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Schizophrenia (SZ) affects approximately 4.5 million people across the European Union (EU) and is associated with annual healthcare and societal costs of 29 billion Euros. The impact on the daily life of patients is huge, ranging from frequent relapses and hospitalisations, the inability to maintain a job or continue scholing, to a low quality of life, impaired cognitive functioning, suicidal ideation and an increase morbidity rate, next to the large burden for carers 1. When diagnosed with schizophrenia or related disorder, patients are commonly prescribed antipsychotics. One-third of the schizophrenia patients are regarded treatment-resistant (TR), meaning that at least two antipsychotic trials have failed. Typically, clozapine is prescribed for TR patients, which is effective for approximately 40% of patients. Clozapine is among the most effective treatments, with the lowest all-cause mortality. Although it is among the most effective antipsychotics, it is generally not used earlier in the illness course due to a small risk of severe neutropenia/agranulocytosis, which is why patients treated with clozapine are intensely monitored. However, this small risk outweighs the burden of not receiving an effective treatment. Since clozapine is among the most effective treatments, this leads to the research question whether earlier initiation of third-line treatment ('early intensified' pharmacological treatment; EIPT) would be more beneficial than the current second-line treatments (treatment as usual; TAU). If this is indeed the case, this could lead to the prevention of unnecessary trials of ineffective treatments, hospitalisations, and recommendations for adaptations of worldwide guidelines as well as a reduction of healthcare and societal costs The INTENSIFY-Schizophrenia trial is part of the larger Horizon 2021 project Psych-STRATA, with the central goal of paving the way for a shift towards a treatment decision-making process tailored for the individual at risk for treatment resistance. To that end, the inestigators aim to establish evidence-based criteria to make decisions of early intense treatment in individuals at risk for treatment resistance across the major psychiatric disorders of schizophrenia, bipolar disorder and major depression. The current protocol focuses on the sample of schizophrenia patients.

Conditions

  • Schizophrenia and Related Disorders
  • Early Treatment-Resistance

Interventions

  • ClozapineDrug

    Participants are randomized to clozapine or second-line antipsychotics. When randomised to clozapine, they will receive clozapine for six weeks.

  • Second-line Antipsychotics (treatment as usual)Drug

    Participants are randomized to clozapine or second-line antipsychotics. When randomized to second-line antipsychotics, this means participants will receive treatment as usual. The physician has the choice to administer any second-line antipsychotic. More specification is not possible, as this is a choice the physician makes with the participant based on the characteristic and preference of the participant (in line with standard clinical practice).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in symptom severity on Positive and Negative Syndrome ScaleTime frame: 6 weeks

Locations

13 sites in 5 countries. Site status is shown where the registry gives one.

  • Medical University Innsbruck

    Innsbruck, Austria · Recruiting

  • Bezirkskliniken Schwaben, Bezirkskrankenhaus Augsburg

    Augsburg, Germany · Not yet recruiting

  • Universitätsklinik für Psychiatrie und Psychotherapie Bielefeld

    Bielefeld, Germany · Recruiting

  • LWL-Klinik Dortmund, Bereich Forschung & Wissenschaft

    Dortmund, Germany · Recruiting

  • University Hospital Frankfurt am Main - Goethe University

    Frankfurt am Main, Germany · Recruiting

  • Klinik für Psychiatrie und Psychotherapie der Universitätsmedizin Mainz

    Mainz, Germany · Recruiting

  • Westfälische Wilhelms-Universität Münster

    Münster, Germany · Recruiting

  • Universita degli Studi di Brescia

    Brescia, Italy · Recruiting

  • University of Cagliari

    Cagliari, Italy · Recruiting

  • Università degli studi della Campania Luigi Vanvitelli

    Naples, Italy · Recruiting

  • Azienda Ospedaliero-Universitaria "Città della Salute e della Scienza di Torino"

    Turin, Italy · Recruiting

  • Fundació Clínic per a la Recerca Biomèdica

    Barcelona, Spain · Recruiting

  • King's College London, Psychiatry & Cognitive Neuroscience

    London, United Kingdom · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.